Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects

Journal of Psychiatry and Neuroscience

Volumn 27, Issue 6, 2002, Pages 429-437

  Delva, Nicholas J ^a,b,f   Brooks, Deborah L ^b   Franklin, Michael ^c   Al Said, Khalid ^b   Hawken, Emily R ^d   Merali, Zul ^e   Lawson, J Stuart ^a   Ravindran, Arun V ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Providence Continuing Care Centre   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f University of Ottawa ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CORTICOTROPIN; DOPAMINE RECEPTOR; GROWTH HORMONE; HYDROCORTISONE; IPSAPIRONE; PROLACTIN; SEROTONIN 1A RECEPTOR; VALPROIC ACID;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MENTAL HEALTH; NORMAL HUMAN; PROLACTIN BLOOD LEVEL;

ADRENOCORTICOTROPIC HORMONE; ADULT; APOMORPHINE; BODY TEMPERATURE; DOPAMINE AGONISTS; HEALTH STATUS; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROLACTIN; PYRIMIDINES; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; TIME FACTORS; VALPROIC ACID;

EID: 0036873996     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48:62-8.
2. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-24.
3. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992;12(Suppl 1):53S-6S.
4. Bowden CL. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998;19:194-9.
5. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Müller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Exerpta Medica; 1984. p. 33-44.
6. Bowden CL. Lithium in comparison to valproate and carbamazepine [presentation]. 20th Congress of the Collegium Internationale Neuro-Psychopharmacologium; 1996 Jun 23-7; Melbourne, Australia.
7. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000;57:481-9.
8. Bohlen P, Huot S, Palfreyman MG. The relationship between GABA concentrations in the brain and cerebrospinal fluid. Brain Res 1979;167:297-305.
9. Loscher W. GABA in plasma and cerebrospinal fluid of different species. Effects of gamma-acetylenic GABA, gamma-vinyl GABA and sodium valproate. J Neurochem 1979;32:1587-91.
10. Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 1997;71:67-76.
11. Meltzer HY, Umberkoman-Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I. Enhanced response in depression and mania. Arch Gen Psychiatry 1984;41:366-74.
12. Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509-23.
13. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992;59:1702-8.
14. Baf MH, Subhash MN, Lakshmana KM, Rao BS. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem Int 1994;24:67-72.
15. Vriend JP, Alexiuk NAM. Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice. Mol Chem Neuropathol 1996;27:307-24.
16. MacDonald RL, Bergey GK. Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res 1979;170:558-62.
17. Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-59.
18. Loscher W, Horstermann D. Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma. Naunyn Schmiedebergs Arch Pharmacol 1994;349:270-8.
19. Hunt SM, Groff JL. Advanced nutrition and human metabolism. St. Paul (MN): West Publishing Company; 1990. p. 158.
20. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990.
21. Cotariu D, Zaidman JL, Evans S. Neurophysiological and biochemical changes evoked by valproic acid in the central nervous system. Prog Neurobiol 1990;34:343-54.
22. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalalgia 1997;17:85-92.
23. Post RM. Biochemical theories of mania. In: Belmaker RH, van Praag HM, editors. Mania: an evolving concept. Lancaster (UK): MTP Press Ltd.; 1980. p. 217-65.
24. Silverstone T, Cookson J. The biology of mania. In: Granville-Grossman K, editor. Recent advances in clinical psychiatry. London: Churchill Livingston; 1982. p. 201-41.
25. Hwang EC, Van Woert MH. Effect of valproic acid on serotonin metabolism. Neuropharmacology 1979;18:391-7.
26. Kempf E, Mack G, Schleef C, Mandel P. Effect of valproic acid on brain serotonin metabolism in isolated and grouped rats. Pharmacol Biochem Behav 1982;17:49-52.
27. Shukla GS. Combined lithium and valproate treatment and subsequent withdrawal: serotonergic mechanism of their interaction in discrete brain regions. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:153-6.
28. Whitton PS, Oreπkovic D, Jernej B, Bulat M. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. J Pharm Pharmacol 1985;37:199-200.
29. Whitton PS, Fowler LJ. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 1991;200:167-9.
30. 1A receptor function in healthy human males: hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology 1997;17:382-90.
31. MacMillan V, Leake J, Chung T, Bovell M. The effect of valproic acid on the 5-hydroxyindoleacetic, homovanillic, and lactic acid levels of cerebrospinal fluid. Brain Res 1987;420:268-76.
32. Zimmer R, Teelken AW, Gündürewa M, Rüther E, Cramer H. Effect of sodium-valproate on CSF GABA, cAMP, cGMP and homovanillic acid levels in men. Brain Res Bull 1980;5(Suppl 2):585-8.
33. Tuomisto J, Männistö P. Neurotransmitter regulation of anterior pituitary hormones. Pharmacological Rev 1985;37:249-332.
34. 1A receptor challenge in anxiety disorders and depression. In: Stahl SM, Gastpar M, Keppel Hesselink JM, Traber J, editors. Serotonin 1A receptors in depression and anxiety. New York: Raven Press Ltd.; 1992. p. 135-62.
35. Lesch K-P, Rupprecht R, Poten B, Müller U, Söhnle K, Fritze J, et al. Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry 1989;26:203-5.
36. Yatham LN, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci 1993;53:447-63.
37. Martin JB, Lal S, Tolis G, Friesen HG. Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin. J Clin Endocrinol Metab 1974;39:180-2.
38. Lal S, Guyda H, Bikadoroff S. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men. J Clin Endocrinol Metab 1977;44:766-70.
39. Lal S, de la Vega CE, Sourkes TL, Friesen HG. Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. J Clin Endocrinol Metab 1973;37:719-24.
40. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman Gilman A, Goodman LS, Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan; 1980. p. 494-534.
41. Elphick M, Yang J-D, Cowen PJ. Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses. Arch Gen Psychiatry 1990;47:135-40.
42. Abraham RR, Dornhorst A, Wynn V, Altaher ARH, Campbell EA, Beckford U, et al. Corticotrophin, cortisol, prolactin and growth hormone responses to insulin-induced hypoglycaemia in normal subjects given sodium valproate. Clin Endocrinol 1985;22:639-44.
43. Sheehan D, Lecrubier Y, Sheehan H, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-57.
44. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
45. Khaitan L, Calabrese JR, Stockmeier CA. Effects of chronic treatment with valproate on serotonin-1A receptor binding and function. Psychopharmacology 1994;113:539-42.
46. Gelfin Y, Lerer B, Lesch K-P, Gorfine M, Allolio B. Complex effects of age and gender on hypothermic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects. Psychopharmacology 1995;120:356-64.
47. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996;153:765-70.
48. Perry PJ, Bever-Stille KA, Arndt S, Gundersen S. Correlation of valproate plasma concentrations and dose in bipolar affective disorder. J Clin Psychopharmacol 2000;20:277-9.
49. Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 1993;54:229-34.
50. Gilmore JH, Ruegg RG, Ekstrom RD, Knight B, Carson SW, Mason GA, et al. Altered prolactin response to clomipramine rechallenge in healthy subjects. Biol Psychiatry 1993;34:885-8.
51. Coiro V, Vescovi PP. Effect of cigarette smoking on ACTH/cortisol secretion in alcoholics after short- and medium-term abstinence. Alcohol Clin Exp Res 1999;23:1515-8.
52. Kirschbaum C, Scherer G, Strasburger CJ. Pituitary and adrenal hormone responses to pharmacological, physical, and psychological stimulation in habitual smokers and nonsmokers. Clin Invest Med 1994;72:804-10.
53. Perkins KA, Sexton JE, DiMarco A. Acute thermogenic effects of nicotine and alcohol in healthy male and female smokers. Physiol Behav 1996;60:305-9.
54. Zachariah SB, Zachariah A, Ananda R, Stewart JT. Hypothermia and thermoregulatory derangements induced by valproic acid. Neurology 2000;55:150-1.
55. 1A reception activation. Eur J Pharmacol 1999;380:R1-3.
56. Lal S, Nair NPV, Guyda H. Effect of lithium on hypothalamic-pituitary dopaminergic function. Acta Psychiatr Scand 1978;57:91-6.
57. Goodnick PJ, Meltzer HY. Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion. J Clin Psychopharmacol 1983;3:239-43.
58. Tanimoto K, Maeda K, Chihara K. Inhibition by lithium of dopamine receptors in rat prolactin release. Brain Res 1981;223:335-42.
59. Meltzer HY, Simonovic M, Sturgeon RD, Fang VS. Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels. Acta Psychiatr Scand Suppl 1981;290:100-21.
60. Rollema H, Lu Y, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997;338:R3-5.